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Objectives. The present study aimed to determine the role of
nitric oxide (NO) and angiotensin-converting enzyme (ACE) in
bradykinin (BK)-induced dilation of human coronary arteries in
vivo.
Background. BK, produced by way of the kinin-kallikrein
system, causes endothelium-dependent vasodilation. However,
little is known about the mechanism of BK-induced dilation of
coronary arteries in humans in vivo.
Methods. The effects of an inhibitor of NO synthesis and of an
ACE inhibitor on BK-induced coronary vasodilation were exam-
ined in 20 patients who had no significant atherosclerotic stenosis
in the artery under study. Lumen diameters of the large epicardial
coronary arteries and coronary blood flow (CBF) were measured
by quantitative coronary arteriography and intracoronary Dopp-
ler technique.
Results. Intracoronary infusion of BK (0.6 and 2.0 mg/min)
increased coronary artery diameter and CBF with no change in
arterial pressure or heart rate. The BK-induced increases in
coronary artery diameter and CBF were significantly reduced
(p < 0.01) after pretreatment with NG-monomethyl-L-arginine
(200 mmol) and were significantly increased (p < 0.01) after
pretreatment with enalaprilat (50 mg).
Conclusions. BK-induced dilation of human large epicardial
and resistance coronary arteries is mediated by NO and increased
by prior ACE inhibition.
(J Am Coll Cardiol 1997;30:108–12)
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The vascular endothelium is involved in the control of vascular
tone by the production of a variety of substances (1,2).
Bradykinin (BK), an endogenous substance produced by
way of the vascular kinin-kallikrein system (3,4), induces
endothelium-dependent vasodilation (5–11). Groves et al. (12)
demonstrated that intracoronary infusion of a selective BK
antagonist reduces the diameter of coronary arteries, coronary
blood flow (CBF) and flow-mediated endothelium-dependent
vasodilation in humans in vivo. These findings suggest a role of
endogenous BK in the control of coronary circulation. How-
ever, little is known concerning the mechanisms of the BK-
induced dilation of human coronary arteries in vivo.
There are inconsistent findings in the published data con-
cerning the contribution of nitric oxide (NO) to BK-induced
coronary vasodilation. Some studies (7–9) show that inhibition
of NO synthesis reduces BK-induced dilation of canine coro-
nary arteries, whereas others (5,6) demonstrate that inhibitors
of NO synthesis have few or only minor effects on BK-induced
dilation of porcine coronary arteries. BK is rapidly inactivated
by kininase II (3,4,13), which is identical to angiotensin-
converting enzyme (ACE). The effects of ACE inhibitors on
BK-induced coronary vasodilation differ among species (8–
10). The difference in the vascular ACE activities to degrade
BK may explain the differing actions of ACE inhibitors among
species. It is therefore important to evaluate the mechanism of
BK-induced coronary dilation of human coronary arteries in
vivo.
The present study aimed to determine the role of NO and
ACE in BK-induced dilation of coronary arteries in humans in
vivo by investigating the effects of an inhibitor of NO synthesis
and of an ACE inhibitor on BK-induced coronary vasodilation
in patients with no significant coronary artery disease.
Methods
Study patients. Twenty patients (13 men, 7 women; mean
age 58 6 11 years) who were undergoing diagnostic coronary
arteriography were studied. All patients had no significant
coronary artery stenosis, as assessed by angiography, in the
artery under study. Patients with significant coronary artery
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disease (diameter stenosis ,50%), previous myocardial infarc-
tion or evidence of left ventricular dysfunction were excluded.
None of the study patients had any ST segment abnormalities
in the rest electrocardiogram (ECG). Five patients had hyper-
cholesterolemia (total cholesterol .220 mg/dl), six had essen-
tial hypertension (systolic blood pressure .140 mm Hg, dia-
stolic blood pressure .90 mm Hg) and six were smokers. No
patient had diabetes mellitus (fasting blood glucose .140
mg/dl or a positive result on glucose tolerance testing).
Quantitative coronary arteriography. We evaluated the
changes in lumen diameter of the large epicardial coronary
arteries at a segment 2 mm distal to the tip of the Doppler wire
that lacked lumen irregularity or atherosclerotic stenosis. We
selected a view that would permit clear visualization of the
coronary segment under study without overlapping branches.
The distance from the X-ray focus to the object and that from
the object to the image intensifier were kept constant during
the study. Coronary angiograms were recorded on 35-mm
cinefilm with use of an angiographic system (Bicor and Hicor,
Siemens-Asahi Inc., Tokyo, Japan). A nonionic contrast me-
dium (Iomeprol, Eisai Co., Tokyo, Japan) was used.
An end-diastolic frame of the angiogram was selected, and
the lumen diameter was determined quantitatively by a densi-
tometric analysis system. The diameter of the segment of
interest was measured three times, and the mean value of these
measurements was used for later analysis. A Judkins catheter
was used to calibrate the lumen diameter in millimeters. The
accuracy and precision of the measurements were as reported
previously (11,14).
Measurement of CBF velocity and CBF. A 6F Judkins
catheter was placed at the orifice of the left main coronary
artery and a 0.018-in. (0.046-cm) or 0.014-in. (0.036-cm)
Doppler-tipped guide wire (FloWire, Cardiometrics Inc.) was
advanced into the proximal portion of the left anterior de-
scending (n 5 16) or the left circumflex (n 5 4) coronary artery
through the Judkins catheter. CBF velocity was measured
continuously and a peak flow velocity was determined by use of
an on-line spectral analyzer (FlowMap, Cardiometrics Inc.).
Peak blood flow velocity spectral signals and their mean values
were monitored continuously. Mean CBF was calculated as
follows (15):
CBF ~ml/min! 5 0.5 3 Average peak flow velocity ~cm/min!
3 Cross-sectional area (cm2).
The cross-sectional area was determined by quantitative
coronary arteriography. Coronary vascular conductance (ml/
minzmm Hg) was estimated from the division of CBF (ml/min)
by mean arterial pressure (mm Hg).
Drugs. BK and NG-monomethyl-L-arginine (L-NMMA)
were purchased from Clinalfa AG, Basel, Switzerland. Enala-
prilat (Vasotec) was a gift of Merck Sharpe & Dohme.
Papaverine was purchased from Dainihon-Seiyaku Co. Each
drug was diluted with physiologic saline solution immediately
before administration.
Study protocol. The study protocol was approved by the
Institutional Review Committee on Human Research, Kyushu
University Faculty of Medicine. Written informed consent was
obtained from each patient.
Cardiac catheterization was performed in the fasting state
after oral premedication with diazepam (5 mg). Three patients
with essential hypertension were taking an ACE inhibitor,
which was discontinued $5 days before the study. Ten other
patients were taking antianginal medications such as calcium
channel blockers and nitrate that were discontinued $24 h
before the study. We examined acetylcholine-induced coronary
vasomotion before L-NMMA administration in 10 of the 20
patients (4 in protocol 1, 5 in protocol 2 and 1 in protocol 3).
In these 10 patients intracoronary infusion of acetylcholine at
3 mg/min increased coronary artery diameter by 11 6 13% and
CBF by 59 6 45%.
Protocol 1. We examined the effect of L-NMMA on BK-
induced coronary vasodilation in six patients. After steady state
baseline systemic arterial pressure, heart rate and blood flow
velocity were recorded, coronary arteriography was performed
to obtain the baseline diameter of the epicardial coronary
artery. BK was then infused at 0.6 mg/min for 1 min into the left
main coronary artery through a Judkins catheter with use of an
infusion pump (1 ml/min). We confirmed in preliminary stud-
ies that intracoronary infusion of saline solution at 1 ml/min
did not affect any of those variables. One minute after initia-
tion of BK infusion, CBF velocity was measured and coronary
arteriography performed. We waited 5 min before administra-
tion of the next higher dose of BK (2.0 mg/min). Before the
infusion of BK, contrast medium in the catheter was withdrawn
to avoid its vasodilating action. During BK infusion, CBF
velocity peaked at about 30 s and reached a plateau by 50 s.
After a 10-min recovery period during which all hemody-
namic variables returned to the baseline level, L-NMMA (200
mmol) was infused into the left coronary artery over 12 min, as
described elsewhere (15). A second infusion of BK was then
administered at the same dose used in the first infusion.
Coronary arteriography was performed as in the first infusion.
We selected this 200-mmol dose of L-NMMA because it
significantly attenuated the acetylcholine-induced increase in
diameter of a large epicardial coronary artery and CBF (15).
Two doses of BK (0.6 and 2.0 kg/min) were administered in
the present study, as preliminary studies had shown that an
intracoronary dose of 0.2 mg/min of BK did not cause signifi-
cant coronary vasodilation, whereas a dose of 6.0 mg/min
caused hypotension.
Protocol 2. We examined the effect of an ACE inhibitor on
BK-induced coronary vasodilation in eight patients. After
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BK 5 bradykinin
CBF 5 coronary blood flow
ECG 5 electrocardiogram
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
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baseline systemic arterial pressure, heart rate, coronary artery
diameter and CBF were recorded, BK (0.6 mg/min) was
infused into a Judkins catheter in the left coronary artery as in
protocol 1. Enalaprilat (50 mg over 2 min) was then infused
into the same artery. BK was then infused at the same dose
used in the initial infusion. Coronary arteriography was per-
formed before and after BK. We selected this dose of enala-
prilat because it had no effect on basal systemic arterial
pressure and heart rate but significantly augmented BK-
induced coronary vasodilation. Because BK (0.6 mg/min) after
enalaprilat significantly decreased systemic arterial pressure,
we did not use the 2.0-mg/min dose of BK after enalaprilat.
Protocol 3. We investigated the possibility of time-related
changes in BK-induced coronary vasodilation in six patients.
Intracoronary infusion of BK at the same dose was repeated
twice in a time sequence similar to that of protocol 1.
Papaverine administration. In all 20 patients, at the end of
each protocol we assessed maximal vasodilator capacity by
administering papaverine (10 mg/5 ml) into the left coronary
artery for 1 min. The papaverine-induced increase in CBF was
recorded as we (14) have previously described.
Statistical analysis. Data are expressed as mean value 6 SD.
Effects of L-NMMA on BK-induced coronary vasodilation were
compared by using two-way analysis of variance, followed by
Bonferroni’s multiple comparison tests. Effects of enalaprilat on
BK-induced coronary vasodilation were compared by Student t
test. A p value ,0.05 was considered statistically significant.
Results
BK-induced coronary vasodilation. Table 1 shows the ef-
fect of BK on mean systemic arterial pressure, heart rate,
lumen diameter of a large epicardial coronary artery and CBF
in all 20 patients. BK increased (p , 0.01) the epicardial
coronary artery diameter and CBF in a dose-dependent man-
ner, but it did not alter systemic arterial pressure or heart rate.
Effect of L-NMMA on BK-induced coronary vasodilation.
Intracoronary administration of L-NMMA (200 mmol) did not
significantly alter basal arterial pressure (85 6 11 and 85 6
12 mm Hg, respectively, before and after L-NMMA), heart rate
(60 6 14 and 58 6 13 beats/min), coronary artery diameter (2.3 6
0.7 and 2.4 6 0.6 mm) or CBF (32 6 19 and 27 6 15 ml/min).
Pretreatment with L-NMMA significantly inhibited the BK-
induced increase in coronary artery diameter and CBF. Percent
changes in BK-induced increases in coronary artery diameter and
CBF were significantly smaller (p , 0.01) after than before
L-NMMA (Fig. 1). BK administration did not alter systemic
arterial pressure or heart rate before or after L-NMMA.
Effect of enalaprilat on BK-induced coronary vasodilation.
Intracoronary administration of enalaprilat (50 mg) did not
alter basal systemic arterial pressure (98 6 13 and 97 6
13 mm Hg, respectively, before and after enalaprilat), heart
rate (58 6 12 and 59 6 13 beats/min), coronary artery diameter
(2.9 6 0.9 and 2.7 6 0.7 mm) or CBF (44 6 16 and 36 6
13 ml/min). Enalaprilat significantly augmented the BK-
induced increase in coronary artery diameter, CBF and coro-
nary vascular conductance, whereas systemic arterial pressure
decreased significantly during BK infusion after enalaprilat
administration. The percent changes in BK-induced increases
in coronary artery diameter, CBF and coronary vascular con-
ductance were significantly greater after enalaprilat (Fig. 2).
Reproducibility of BK-induced coronary vasodilation. The
increase in coronary diameter and CBF did not differ
Table 1. Effect of Bradykinin on Systemic Arterial Pressure, Heart
Rate, Coronary Artery Diameter and Coronary Blood Flow
Baseline
Value
After Bradykinin
(mg/min)
0.6 2.0
Mean arterial pressure (mm Hg) 97 6 13 97 6 13 94 6 14
Heart rate (beats/min) 61 6 13 60 6 14 62 6 14
Coronary artery diameter (mm) 2.6 6 0.8 2.8 6 0.8* 3.0 6 0.8*
Coronary blood flow (ml/min) 41 6 27 79 6 46* 107 6 65*
*p , 0.01 versus baseline value. Data shown are mean value 6 SD (n 5 20).
Figure 1. BK-induced increases in coronary artery diameter (A) and
CBF (B) before and after L-NMMA in six patients. BK did not affect
systemic arterial pressure or heart rate during the study. Data are
shown as mean value 6 SD (n 5 6). **p , 0.01 before and after
L-NMMA by two-way analysis of variance.
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significantly between the first and second administration of
BK (Fig. 3).
Papaverine-induced coronary vasodilation. There was no
significant difference in percent increases in CBF among
patients of protocol 1 (285 6 29%), protocol 2 (302 6 65%)
and protocol 3 (296 6 52%).
Discussion
Role of NO and ACE in BK-induced human coronary
arteries in vivo. BK that is produced by way of the vascular
kinin-kallikrein system (3,4,13) stimulates the release of NO,
prostacyclin or endothelium-derived hyperpolarizing factor,
alone or in combination, from vascular endothelial cells and,
thus, causes endothelium-dependent coronary vasodilation (3–
11). The relative contribution of these endothelium-derived
substances to BK-induced coronary vasodilation differs among
species and with the specific vascular beds being investigated.
Little is known about the role of NO in BK-induced dilation of
human coronary arteries in vivo. In the present study, BK
increased coronary artery diameter and CBF without affecting
systemic arterial pressure or heart rate, indicating that BK
caused the dilation of large epicardial and resistance coronary
arteries. Pretreatment with L-NMMA markedly reduced the
BK-induced increases in arterial diameter and CBF. We (15)
previously reported that L-NMMA, at the dose used in the
present study, inhibited the acetylcholine-induced increases in
coronary artery diameter and CBF in patients with normal
coronary arteriograms. Quyyumi et al. (16) reported similar
findings. These findings suggest that the dilation of large epicar-
dial and resistance coronary arteries induced by BK is mediated
mainly by endothelium-derived NO in humans in vivo.
Figure 2. BK-induced increases in coronary artery diameter (A), CBF
(B) and coronary vascular conductance (C) before (open bars) and
after (closed bars) the administration of enalaprilat in eight patients.
BK (0.6 mg/min) did not affect systemic arterial pressure before
enalaprilat but decreased it significantly from 98 6 13 to 80 6
12 mm Hg (p , 0.05) after enalaprilat. BK did not alter heart rate
before or after enalaprilat. Data shown are mean value 6 SD (n 5 8).
*p , 0.05, **p , 0.01 versus before enalaprilat by paired t test.
Figure 3. Increases in coronary artery diameter (A) and CBF (B) in six
patients after the first and second administration of BK. BK did not
affect systemic arterial pressure or heart rate during the study. Data
shown are mean value 6 SD (n 5 6). NS 5 difference not significant.
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Because ACE is identical to kininase II and present on the
vascular endothelium, BK is inactivated by ACE (3,4,13). It is
thus assumed that ACE inhibitors may act on kininase II and
increase the tissue concentrations of BK which, in turn, augment
the vasodilation induced by BK, leading to an increase in NO
synthesis. Sudhir et al. (17) showed that in dogs vasodilation of
resistance coronary arteries induced by an ACE inhibitor was
totally inhibited by the bradykinin receptor antagonist whereas
ACE inhibitor-induced vasodilation of large epicardial coronary
arteries was reduced by L-NMMA. However, the effect of ACE
inhibition on BK-induced dilation of human coronary arteries had
not been investigated. Pretreatment with enalaprilat in the
present study significantly augmented BK-induced increases in
arterial diameter and CBF. Because systemic arterial pressure
decreased significantly after enalaprilat, we calculated the coro-
nary vascular conductance and found that the BK-induced in-
crease in coronary vascular conductance was significantly greater
after enalaprilat. The hypotension induced by BK after enalapri-
lat may be attributable to an unmasking of the BK-induced
vasodilation of the systemic vasculature after ACE inhibition.
These findings suggest that BK-induced dilation of human large
epicardial and resistance coronary arteries is augmented after
enalaprilat. This effect of enalaprilat appeared to result from an
inhibition of BK breakdown induced by the inhibition of vascular
ACE.
We evaluated the reproducibility of the BK-induced vaso-
dilation to determine whether the vasodilator effect of BK
would be smaller at its second administration than at its first
because of tachyphylaxis (18). Our results indicate that the
effects of L-NMMA and enalaprilat were not related to time.
Limitations of the study. A major limitation of the present
study is the small number of patients studied. Thus, we could
not determine whether the BK-induced vasodilation was im-
paired in the presence of certain cardiovascular disorders.
Further studies are needed to elucidate a possible relation
between BK-induced vasodilation and disorders such as hyper-
cholesterolemia, atherosclerosis, hypertension, left ventricular
hypertrophy, and heart failure.
Summary and clinical implications. The present study
showed that BK-induced dilation of human large epicardial
and resistance coronary arteries was inhibited by L-NMMA, an
inhibitor of NO synthesis, and was increased by enalaprilat, an
ACE inhibitor. Our findings have several implications 1) the
results may contribute to wider use and better understanding
of ACE inhibitors. 2) Our data indicate that NO is responsible
for BK-induced dilation of human coronary arteries in vivo.
We (11) and other investigators (19) showed that BK-induced
dilation was impaired at the atherosclerotic site of human
coronary arteries. Thus, it is likely that impaired BK-induced
dilation at the atherosclerotic site is mediated by a reduction in
the release of NO. 3) The potentiation of the BK-induced
vasodilation by enalaprilat suggests that, in addition to inhib-
iting angiotensin II formation, ACE inhibitors increase the
release of NO by an increased tissue concentration of BK. The
TREND study by Mancini et al. (20) has shown that treatment
with an ACE inhibitor, quinapril, lessens endothelial dysfunc-
tion in patients with angiographically normal or minimally
decreased coronary arteries. Thus, the TREND study might
strengthen our present observation that an ACE inhibitor,
enalaprilat, increased the BK-induced release of NO.
References
1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the
regulation of arterial smooth muscle by acetylcholine. Nature 1980;288:373–6.
2. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med
1993;329:2002–12.
3. Oza NB, Schwartz JH, Gould HD, Levinsky NG. Rat aortic smooth muscle
cells in culture express kallikrein kininogen and bradykininase activity. J Clin
Invest 1990;85:597–600.
4. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Phar-
macol Rev 1990;32:1–46.
5. Richard V, Tanner F, Tschudi M, Lu¨scher TF. Different activations of
L-arginine pathway by bradykinin, serotonin, and clonidine in coronary
arteries. Am J Physiol 1990;259:H1433–9.
6. Tschudi M, Richard V, Bu¨hler FR, Lu¨scher TF. Importance of endothelium-
derived nitric oxide in porcine coronary resistance arteries. Am J Physiol
1991;260:H13–20.
7. Pelc LR, Gross GJ, Warltier D. Mechanisms of coronary vasodilation
produced by bradykinin. Circulation 1991;83:2048–56.
8. Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Poten-
tiation of endothelium-dependent relaxation to bradykinin by angiotensin
1-converting enzyme inhibitors in canine coronary artery involves both
endothelium-derived relaxing and hyperpolarizing factors. Circ Res 1992;71:
137–44.
9. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent
vasodilator effect of angiotensin-converting enzyme inhibitors: role of bra-
dykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992;20
Suppl 9:S74–83.
10. Zanzinger J, Zheng X, Bassenge E. Endothelium-dependent vasomotor
responses to endogenous agonist are potentiated following ACE inhibition
by a bradykinin dependent mechanism. Cardiovasc Res 1994;28:209–14.
11. Kuga T, Egashira K, Mohri M, et al. Bradykinin-induced vasodilation is
impaired at the atherosclerotic site but is preserved at the spastic site of
human coronary arteries in vivo. Circulation 1995;92:183–9.
12. Groves P, Kurz S, Just H, Drexler H. Role of bradykinin in human coronary
vasomotor control. Circulation 1995;92:3424–30.
13. Erdo¨s EG. Angiotensin-converting enzyme and the change in our concept
through the years. Hypertension 1990;26:363–70.
14. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response
to acetylcholine in patients with coronary risk factor and proximal athero-
sclerotic lesions. J Clin Invest 1993;91:29–37.
15. Egashira K, Katsuda Y, Mohri M, et al. Role of endothelium-derived nitric
oxide in coronary vasodilation induced by pacing tachycardia in humans. Circ
Res 1996;79:331–5.
16. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the
human coronary circulation: impact of risk factors for coronary atheroscle-
rosis. J Clin Invest 1995;95:1747–55.
17. Sudhir K, Chou TM, Hutchinson SJ, Chatterjee K. Coronary vasodilation
induced by angiotensin-converting enzyme inhibition in vivo: differential
contribution of nitric oxide and bradykinin in conductance and resistance
arteries. Circulation 1996;93:1734–9.
18. Olmos L, Mombouli JV, Illiano S, Vanhoutte PM. cGMP mediates the
desensitization to bradykinin in isolated canine coronary arteries. Am J
Physiol 1995;268:H865–70.
19. Rafflenbeul W, Bassenge E, Lichtlen P. Competition between endothelium-
dependent and nitroglycerin-induced coronary vasodilation. Zeitschrift fur
Kardiologie 1989;78 Suppl 2:45–7; discussion 64–67.
20. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme
inhibition with quinapril improves endothelial vasomotor dysfunction in
patients with coronary artery disease: the TREND study. Circulation 1996;
94:258–65.
112 KUGA ET AL. JACC Vol. 30, No. 1
BRADYKININ-INDUCED CORONARY VASODILATION July 1997:108–12
